meconiumaspirationsyndrome[1]
Post on 27-Jan-2016
213 Views
Preview:
DESCRIPTION
TRANSCRIPT
MECONIUM ASPIRATION SYNDROME
Ismail HaronConsultant Paediatrician & Neonatologist
Hospital Sungai Buloh
Symposium 4: Challenges in neonatal care
SMC/KL/2008
Introduction
Epidemiology
Pathogenesis of MAS
Clinical features
ManagementGeneralSpecific
Conclusion
Challenges in neonatal care: Meconium Aspiration Syndrome
SMC/KL/2008
IntroductionMeconium aspiration syndrome (MAS) is not an uncommon problem.
Important cause of respiratory distress in the term newborn with high morbidity and mortality.
The pathophysiology is complex and is not well defined.
Despite advances in neonatal intensive care over the last 2 decades, MAS remains one the most vexing clinical conditions to manage.
SMC/KL/2008
Composition of meconium
Sterile compound made primary of water (75%), with mucous glycoproteins, lipids and proteases.
Small dried amniotic fluid debris, vernix and lanugo.
Bile pigments.
The residue from intestinal secretions.
SMC/KL/2008
Epidemiology
SMC/KL/2008
Epidemiology
Approximately 10 – 15% of all live births are complicated by meconium stained amniotic fluid (MSAF).
About 5% of neonates born through MSAF develop MAS.
MSAF and MAS related to advanced gestation.
Generally incidence of MSAF and MAS are in a declining trend.
SMC/KL/2008
Yoder BA et al. Obstet Gynecol 2002;99:731-9Dargaville PA, Copnell B. Pediatrics 2006;117:1712-1721
Incidence of MAS according to gestation
SMC/KL/2008
Yoder BA et al. Obstet Gynecol 2002;99:731-9Dargaville PA, Copnell B. Pediatrics 2006;117:1712-1721
Incidence of MAS
SMC/KL/2008
Pathogenesis of MAS
SMC/KL/2008
Causes of MSAFUnder normal circumstances, the passage of meconium from the fetus into the amnion is prevented by;
Lack of intestinal peristalsis (low motilin level)Tonic contraction of anal sphincterTerminal cap of viscous meconium
Fetal maturation – post-term. Vagal stimulation produced by head or cord compression in the absence of fetal distress. In-utero stress (hypoxia and acidosis) producing relaxation of anal sphincterPresence of meconium in the amniotic fluid may increase the risk of intraamniotic infection.
Piper HM et al. Obstet Gynecol 1998;91:741-5
SMC/KL/2008
Risk factorsMaternal hypertensionMaternal diabetes mellitusMaternal heavy cigarette smoking.Maternal chronic respiratory or CVS disease.Post-term pregnancy.Pre-eclampsia / eclampsiaOligohydramniosIntrauterine growth retardationPoor biophysical profileAbnormal fetal heart rate patterns
SMC/KL/2008
Causes of MAS
Reason why some infants born through MSAF develop an aspiration syndrome whereas others do not – unclear.
Aspiration of meconium may occur in-utero or after delivery with the first few breaths.
Chronic fetal hypoxia and acidosis may lead to fetal gasping and the subsequent in-utero aspiration of meconium.
Chronic in-utero insult may be responsible for most cases of severe MAS as opposed to an acute peripartum event.
Blackwell SC et al. Am J Obstet Gynecol 2001;184:1422-6Ghidini A, Spong CY. Am J Obstet Gynecol 2001;185:931-8
SMC/KL/2008
Mechanisms of injury
Mechanical obstruction of airways.
Chemical pneumonitis.
Vasoconstriction of pulmonary vessels.
Inactivation of surfactant.
Activation of complement.
SMC/KL/2008
Mechanical obstruction of airwaysMechanism of injury – cont’
Thick and viscous.Complete or partial airway obstruction.With onset of respiration – meconium migrates from central to peripheral airways.Complete obstruction – atelectasisPartial obstruction –
Ball-valve – air trapping.Risk of pneumothorax - 15 – 33%
Cleary GM, Wiswell TE. Pediatr Clin North Am. 1998;45:511-29
V/Q mismatch
SMC/KL/2008
PneumonitisMechanism of injury – cont’
Neutrophils & Macrophages (alveoli, airway & parenchyma)
Cytokines(TNFα, IL-1β, IL-8)
Pneumonitis
Vascular leakage
Haemorrhagic pulmonary oedema
Bodil S et al. Pediatrics 2008;121:e496-e505Kaoru O et al. Pediatrics 2008;121:e748-e753
SMC/KL/2008
Vasoconstriction of pulmonary vesselsMechanism of injury – cont’
Severe MAS may be complicated by PPHN.
Pulmonary vasoconstriction is in part may be a result of the underlying inutero stress.
The release of vasoactive mediators as a result of injury from meconium;
Eicosanoids, Endothelin-1Prostaglandin E2
Hageman JR, Caplan MS. Clin Perinatol 1995;22:251-261
SMC/KL/2008
Inactivation of surfactantMechanism of injury – cont’
In the early 1990s – meconium inactivates surfactant.
Meconium displaces surfactant from the alveolar surface→ inhibits surface tension-lowering ability.
Direct inhibitory effect of meconium on the function of surfactant in vitro an in in vivo animal models.
Surfactant deficiency due to inactivation leads to increased surface tension;
AtelectasisDecreased lung complianceDecreased lung volumes
Findlay RD et al. Pediatrics 1996;97:48-52
Greenough A. Eur J Pediatr 1995;154:S2-4
Cleary GM et al. Pediatrics 1997;100:998-1003 Higgins ST et al. Pediatr Res 1996;39:443-7
SMC/KL/2008
Activation of complementMechanism of injury – cont’
Meconium is a potent activator of the complement system.
Activation of complement system was correlated with lung dysfunction and mortality.
Meconium-induced cytokines production is mediated by complement and CD14.
Castellheim A et al. Pediatr Res 2004;55(2):310-318Castellheim A et al. Scand J Immunol 2005;61(3):217-225
Lindenskov PH et al. Pediatr Res 2004;56(5):810-817
Bodil S et al. Pediatrics 2008;121:e496-e505
SMC/KL/2008
Physiologic meconium passage(particularly if postdates)
Fetal compromise (hypoxia, cord compression, etc) – meconium passage
Meconium-stained amniotic fluid Umbilical cord spasm
Continued compromiseInutero gaspingPostpartum aspiration
Meconium aspiration
Peripheral airway obstruction
Proximal airway obstruction Cytokines activation Inactivation of surfactant
Pneumonitis
AcidosisHypoxemia
Hypercapnea
AcidosisHypoxemia
Hypercapnea
Remodeling of pulmonary vasculature
(muscular hyperplasia)
PPHN
Decreased lung compliance
Complete
Atelectasis
Vasoactive mediators
Partial
V/Q mismatch
Ball-valve effect
Air trapping
Air leaks
SMC/KL/2008
Clinical features
SMC/KL/2008
Diagnosis
MAS must be considered in any infant born through MSAF who develops symptoms of respiratory distress.
Various radiographic findings may be present.
Diffuse asymmetric patchy infiltrates
Areas of atelectasis
Hyperinflated areas
SMC/KL/2008
SMC/KL/2008
SMC/KL/2008
SMC/KL/2008
Diagnosis
MildRequires < 40% oxygen for less than 48 hours
Moderate.Requires > 40% oxygen for more than 48 hours No air leak
SevereRequires assisted ventilation for more than 48 hoursOften associated with PPHN
Severity of MAS
Cleary GM, Wiswell TE. Pediatr Clin North Am 1998;45:511-29
SMC/KL/2008
Management
SMC/KL/2008
Prevention
Prevention
Prevention
Prevention
Prevention
SMC/KL/2008
Antepartum
Intrapartum
Postnatal
SMC/KL/2008
TreatmentGeneral
Temperature regulation
Haemodynamic status
Biochemistry
Haematology
Possible infection
Associated asphyxia
SMC/KL/2008
SMC/KL/2008
TreatmentRespiratory management
Depends on the amount of respiratory distress.
Increasing oxygenation while minimising barotrauma/volutrauma.
Hyperventilation did not proven beneficial.
No randomised trials have compared different forms of ventilation in MAS.
SMC/KL/2008
TreatmentMode of ventilation
HFV claimed to be gentler.
Theoretically, HFV should reduce air leaks.
HFV may slow the progression of meconium down the tracheobronchial tree and allow more time for meconium removal.
Hachey WE et al. Crit Care Med 1998;26:556-61
SMC/KL/2008
TreatmentSurfactant Therapy
Two randomised trials – evaluate the efficacy of exogenous surfactant therapy in MAS showed promising results with decrease in the number of infants requiring ECMO and possible reduction of pneumothorax.
Cochrane meta-analysis – 4 randomised trials;Reduce the use of ECMO (RR 0.64)No effect on mortality
Findlay RD et al. Pediatrics 1996;97:48-52Lotze A et al. J Pediatr 1998;132:40-7
El Shahed A et al. Cochrane Database Syst Rev 2007
SMC/KL/2008
TreatmentSurfactant Therapy
Surfactant inactivation property of meconium.
Search for new synthetic surfactant preparations; highly resistant to inactivation by meconium.
Herting E et a. Pediatr Res 2001;50:44-9
SMC/KL/2008
TreatmentSurfactant Lavage
Removal of noxious material from the lungs.Minimised obstruction.Offset the inactivation of surfactant by meconiumIncrease oxygenation & reduction in duration of mechanical ventilation
LessMAS Trial.
Lam BCC, Yeung CY. Pediatrics 1999;103:1014-8Wiswell TE et al. Pediatrics 2002;109:1081-7
SMC/KL/2008
Aetiology of PPHN
Clark RH et al. N Engl J Med. 2000;342:469-74
SMC/KL/2008
TreatmentInhaled nitric oxide
Selective pulmonary vasodilation.
Activate guanylate cyclase and increases cyclic GMP and acting directly on the vascular smooth muscle.
Decreased need for ECMO (RR 0.61) but no difference in mortality.
Pretreatment with surfactant improves in delivery of iNO to the alveoli.
Finer NN, Barringtan KJ. Cochrane Database Syst Rev 2006
Rais-Bahrami KRO et al. Crit Care Med 1997;25(10):1744-7
SMC/KL/2008
TreatmentInhaled nitric oxide
HFOV + iNO seems to work better, likely due to improve lung inflation and better delivery of the drug.
Kinsella JP et al. J Pediatr 1997;131:55-62
SMC/KL/2008
(RR:0.6)
Clark RH et al. N Engl J Med. 2000;342:469-74
(RR:0.6)(RR:0.6)(RR:0.6)
SMC/KL/2008
TreatmentSteroid
Insufficient evidence to assess the effects of steroid therapy in the management of MAS.
Ward M, Sinn J. Cochrane Database Syst Rev 2003
SMC/KL/2008
Thank you for your kind attention
top related